Network Insights Methodology Get Access

Roche

ORG Health Care / Pharmaceuticals Momentum 6.5ML Momentum Score (0-100). Weighted composite of 9 features: mention velocity, article breadth, relationship density, deal context, recency, market cap, enrichment completeness, mention concentration, entity type. NORMALPSI regime classification. QUIET (<0.3): baseline activity. NORMAL (0.3-0.5): typical deal flow. ELEVATED (0.5-0.7): above-average signals. HIGH (0.7-0.85): significant activity. EXTREME (>0.85): exceptional signal concentration. Primary: Spectral Shift

$290B market cap (Basel) ranks among top three global pharma companies by revenue. Roche Diagnostics and pharmaceutical divisions lead oncology, virology, and personalized healthcare segments; recent AI partnerships in precision cancer diagnostics reflect shift toward computational medicine.

Referenced in healthcare AI and precision oncology ecosystem; associated with partnerships in cancer diagnostics and AI-driven drug development through entities like Owkin and Waiv.
-0.29
PSI ScorePlocamium Signal Index - composite z-score from 5 orthogonal signals: news frequency, targeted sentiment, graph centrality, regulatory filings, and clinical trial activity.
6.5
MomentumML Momentum Score (0-100). Weighted composite of 9 features including mention velocity, article breadth, deal context, and relationship density. Retrained weekly.
1%
ConfidenceSignal confidence - percentage of PSI sub-signals with sufficient data (30+ observations). Higher confidence means the PSI score is based on more complete data.
5
ConnectionsDegree centrality - number of unique entities this entity co-occurs with in news signals and articles. Higher = more connected in the intelligence network.
Connected Entities
PlocamiumAI Merck Europe Novartis AstraZeneca
Watch This Entity
PSI Intelligence
30-Day Trend
2026-05-28 2026-05-30 6 0 Degree Mentions
Signal Decomposition
Attention Cascade
3.333
Narrative Drift
0.000
Spectral Shift
433.635
Sentiment-Momentum Divergence
0.000
Source Concentration
0.615
Peer Comparison
Not yet ranked. Sector-relative scoring requires at least four entities in the same BICS sector with PSI history; this entity does not yet meet the threshold or sits in a sector with insufficient peers.
Network Analysis
5 Degree Centrality
Ego Network (top connections)
PlocamiumAI (weight 3.0)Merck (weight 3.0)Europe (weight 2.0)Novartis (weight 2.0)AstraZeneca (weight 2.0) PlocamiumAIMerckEuropeNovartisAstraZeneca Roche (degree 5) Roche
Centrality History
2026-05-28 2026-05-30 6 0 Degree Mentions
EntityWeight StatusFirst Seen
PlocamiumAI 3 NEW
Merck 3 NEW
Europe 2 NEW
Novartis 2 NEW
AstraZeneca 2 NEW
Article Coverage (18)
DateLaneTitle
2026-05-27 Healthcare Marketing Roche Bets Billions on PathAI to Leapfrog Rivals in the Race For AI-Powered Pathology
2026-05-09 Healthcare M&A Roche Acquires PathAI to Control the Diagnostic Layer That Determines Which Patients Get Which Drugs
2026-05-09 Healthcare M&A Roche Acquires PathAI to Control the Diagnostic Layer That Determines Which Patients Get Which Drugs
2026-05-09 Healthcare M&A Roche Acquires PathAI to Control the Diagnostic Layer That Determines Which Patients Get Which Drugs
2026-05-09 Healthcare M&A Roche Acquires PathAI to Control the Diagnostic Layer That Determines Which Patients Get Which Drugs
2026-05-09 Healthcare M&A Roche Acquires PathAI to Control the Diagnostic Layer That Determines Which Patients Get Which Drugs
2026-05-09 Healthcare M&A Roche Acquires PathAI to Control the Diagnostic Layer That Determines Which Patients Get Which Drugs
2026-05-09 Healthcare M&A Roche Acquires PathAI to Control the Diagnostic Layer That Determines Which Patients Get Which Drugs
2026-05-09 Healthcare M&A Roche Acquires PathAI to Control the Diagnostic Layer That Determines Which Patients Get Which Drugs
2026-05-09 Healthcare M&A Roche Acquires PathAI to Control the Diagnostic Layer That Determines Which Patients Get Which Drugs
2026-05-09 Healthcare M&A Roche Acquires PathAI to Control the Diagnostic Layer That Determines Which Patients Get Which Drugs
2026-05-09 Healthcare M&A Roche Acquires PathAI to Control the Diagnostic Layer That Determines Which Patients Get Which Drugs
2026-05-09 Healthcare M&A Roche Acquires PathAI to Control the Diagnostic Layer That Determines Which Patients Get Which Drugs
2026-05-09 Healthcare M&A Roche Acquires PathAI to Control the Diagnostic Layer That Determines Which Patients Get Which Drugs
2026-03-28 Healthcare M&A China's Biotech Boom Is Rewriting Everything
2026-03-27 Healthcare M&A Novartis to Spend Up to $2B on Excellergy and Its Next-Gen Xolair Candidate
2026-03-13 Healthcare M&A Startup Waiv Spins Out of Owkin With $33M to Bring AI Precision to Cancer Decisions
2026-03-13 Healthcare M&A Startup Waiv Spins Out of Owkin With $33M to Bring AI Precision to Cancer Decisions

Request Access

Full PSI intelligence, network analysis, EDGAR filings, and predicted links require an access token.

Data as of 2026-05-30 ← Intelligence Network